Clinical trial · Observational
Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Evaluation of Normal Tissue Toxicities in Head and Neck Cancer Patients Receiving Intensity Modulated Radiotherapy (IMRT)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Tests that measure how much saliva is made, hearing, swallowing, voice function, and quality of life may improve the ability to plan treatment for patients with advanced head and neck cancer and may help doctors find better ways to treat the cancer. PURPOSE: This clinical trial is studying the side effects of high-dose intensity-modulated radiation therapy in treating patients with advanced head and neck cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Long-term Effects Secondary to Cancer Therapy in Adults | — | UNRESOLVED | — |
| Oral Complications of Radiation Therapy | — | UNRESOLVED | — |
| Radiation Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| intensity-modulated radiation therapy | Radiation | — | UNRESOLVED |
| management of therapy complications | Procedure | — | UNRESOLVED |
| quality-of-life assessment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Stimulated saliva production at 6 months after completion of intensity-modulated radiotherapy (IMRT)
- measure
- Comparison of salivary function of patients in current study to salivary function of historical controls
Secondary outcomes (4)
- measure
- Auditory, swallow, and voice function at 6 months after completion of IMRT
- measure
- Quality of Life (QOL) as assessed at baseline and at 1, 6, and 12 months after completion of IMRT
- measure
- Toxicities as measured by NCI CTCAE v3.0
- measure
- Improvement in IMRT/tomotherapy field design
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed advanced head and neck cancer * Indication for radiotherapy or chemoradiotherapy as primary or postoperative therapy AND meets 1 of the following criteria: * More than 75% of bilateral parotid glands expected to receive ≥ 45 cGy of radiation using conventional treatment field design * Either or both central auditory apparatus predicted to receive \> 45 cGy of radiation PATIENT CHARACTERISTICS: * No comorbid medical condition that would preclude radiotherapy * No serious concurrent psychosocial, familial, sociological, geographical, or other condition that would preclude study compliance PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available